Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study
Background Inhibitory effects of denosumab on bone remodeling are reversible and disappear once treatment is discontinued. Herein, we examined whether and to what extent delayed denosumab administration is also associated with fracture risk using nation-wide data. Methods The study cohort included w...
Saved in:
Main Authors: | Kyoung Min Kim, Seol A Jang, Nam Ki Hong, Chul Sik Kim, Yumie Rhee, Seok Won Park, Steven R. Cummings, Gi Hyeon Seo |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Endocrine Society
2024-12-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.e-enm.org/upload/pdf/enm-2024-2047.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
by: Aysun Seker, et al.
Published: (2025-01-01) -
Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
by: Shouyu Xiang, et al.
Published: (2025-01-01) -
Denosumab usage in atypical cemento-osseous dysplasia involving the entire mandible: a case report
by: Chieh Ling Chiang, et al.
Published: (2025-01-01) -
Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
by: DENO Research Group, et al.
Published: (2025-01-01) -
Effects of Neoadjuvant Denosumab on Radiological and Histological Responses in Patients Undergoing En Bloc Resection for Giant Cell Tumor of Bone: A Systematic Review
by: Hendra Aditama, et al.
Published: (2024-10-01)